Xiaohong Cai Selected Research

Xiaohong Cai Research Topics

Disease

7	Hypoxia (Hypoxemia) 01/2022 - 04/2007
6	Neoplasms (Cancer) 01/2019 - 03/2007
4	Obstructive Sleep Apnea 01/2022 - 03/2015
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2014 - 12/2002
2	Asthma (Bronchial Asthma) 11/2019 - 05/2013
2	Stomach Neoplasms (Stomach Cancer) 11/2017 - 07/2009
1	Apnea 01/2022
1	Cognitive Dysfunction 01/2020
1	COVID-19 01/2020
1	Memory Disorders (Memory Loss) 01/2020
1	Respiratory Tract Infections (Respiratory Tract Infection) 11/2019
1	Venous Thromboembolism 03/2019
1	Fibrosis (Cirrhosis) 02/2019
1	Inflammation (Inflammations) 02/2019
1	Non-alcoholic Fatty Liver Disease 02/2019
1	Hepatocellular Carcinoma (Hepatoma) 01/2019
1	Blindness (Hysterical Blindness) 01/2017
1	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2017
1	Pathologic Neovascularization 01/2017
1	Hyperoxia 01/2017
1	Lung Neoplasms (Lung Cancer) 05/2014
1	Liver Diseases (Liver Disease) 06/2012
1	Diarrhea 06/2012
1	Hematologic Neoplasms (Hematological Malignancy) 05/2008
1	Pancreatic Neoplasms (Pancreatic Cancer) 05/2008
1	Adenocarcinoma 05/2008
1	Carcinogenesis 04/2007
1	von Willebrand Diseases (von Willebrand's Disease) 05/2006

Drug/Important Bio-Agent (IBA)

3	Pharmaceutical PreparationsIBA 01/2022 - 04/2007
3	Messenger RNA (mRNA)IBA 02/2019 - 05/2013
2	Caffeine (No Doz)FDA LinkGeneric 01/2022 - 01/2017
2	Oxygen (Dioxygen)IBA 01/2017 - 04/2007
2	Proteins (Proteins, Gene)FDA Link 05/2013 - 04/2007
2	Cisplatin (Platino)FDA LinkGeneric 06/2012 - 12/2002
2	Gemcitabine FDA Link 06/2012 - 12/2002
1	sulforaphaneIBA 01/2022
1	TESIBA 01/2022
1	Volatile Fatty AcidsIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	AntioxidantsIBA 01/2022
1	Neuroprotective AgentsIBA 01/2020
1	1,3-dipropyl-8-cyclopentylxanthineIBA 01/2020
1	Adenosine A1 ReceptorIBA 01/2020
1	Protein Kinase CIBA 01/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2019
1	Protein SIBA 03/2019
1	Protective AgentsIBA 02/2019
1	ResveratrolIBA 02/2019
1	LipidsIBA 02/2019
1	CurcuminIBA 02/2019
1	CytokinesIBA 02/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Circular RNAIBA 01/2019
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Long Noncoding RNAIBA 01/2019
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2017
1	Adenosine (Adenocard)FDA LinkGeneric 01/2017
1	Retinaldehyde (Retinal)IBA 01/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017
1	montelukast (Singulair)FDA Link 03/2015
1	MetallothioneinIBA 01/2014
1	ErbB Receptors (EGF Receptor)IBA 01/2014
1	Phosphatidylinositols (Phosphatidylinositol)IBA 05/2013
1	Cyclin D1IBA 05/2013
1	OvalbuminIBA 05/2013
1	Cyclin AIBA 05/2013
1	EndostatinsIBA 06/2012
1	ProdrugsIBA 03/2012
1	NucleotidesIBA 03/2012
1	DNA (Deoxyribonucleic Acid)IBA 03/2012
1	TH 302IBA 03/2012
1	isophosphamide mustard (IPAM)IBA 03/2012
1	azomycinIBA 03/2012
1	Irinotecan (Camptosar)FDA LinkGeneric 07/2009
1	Fluorouracil (Carac)FDA LinkGeneric 07/2009
1	Leucovorin (Folinic Acid)FDA Link 07/2009
1	Tubulin ModulatorsIBA 05/2008
1	stirocainideIBA 05/2008
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 05/2008
1	multidrug resistance-associated protein 1IBA 05/2008
1	Antineoplastic Agents (Antineoplastics)IBA 05/2008
1	NocodazoleIBA 04/2007
1	Transcription Factors (Transcription Factor)IBA 04/2007
1	Topotecan (Hycamtin)FDA LinkGeneric 04/2007
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 04/2007
1	topovaleIBA 04/2007
1	Topoisomerase I InhibitorsIBA 04/2007
1	AcetyleneIBA 03/2007
1	Cytotoxins (Cytolysins)IBA 03/2007
1	IndazolesIBA 03/2007
1	von Willebrand FactorIBA 05/2006
1	Carboplatin (JM8)FDA LinkGeneric 12/2002

Therapy/Procedure

4	Therapeutics 01/2022 - 04/2007
3	Drug Therapy (Chemotherapy) 11/2017 - 12/2002
2	Blood Transfusion (Blood Transfusions) 01/2020 - 05/2014